[Special Stock] SK Bioscience Wins Pneumococcal Vaccine Lawsuit Against Pfizer... Stock Price Rises

On the 10th in the stock market, SK Bioscience's stock price rose sharply despite political instability caused by martial law. The stock price rebounded following news that it won a lawsuit related to the PCV (pneumococcal conjugate vaccine) filed by global pharmaceutical company Pfizer.

SK Bioscience closed at 49,400 KRW, up 10.251% from the previous day's closing price. The stock started with an upward trend in the early session and significantly expanded its gains in the afternoon.

According to the bio industry, SK Bioscience won the patent infringement lawsuit against Pfizer's subsidiary, Wyeth LLC, on that day.

Pfizer had filed a lawsuit claiming that SK Bioscience's pneumococcal 13-valent vaccine, "SkyNuvomopraphil Syringe," developed in 2016 and approved by the Ministry of Food and Drug Safety, infringed on the patent of its "Prevnar 13."

After losing the first trial in January 2018, SK Bioscience halted production and sales of SkyNuvomopraphil Syringe until 2027, the patent expiration date of Prevnar 13, following the court's recommendation for reconciliation.

Subsequently, SK Bioscience signed a technology transfer contract for vaccine research purposes with a Russian pharmaceutical company that Pfizer had not registered the patent rights with. Pfizer filed another lawsuit, but the court ruled in favor of SK Bioscience.